Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01562158 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT01562158 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 100 participants.
The verdict
NCT01562158, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the efficacy of placebo and activated recombinant human factor VII in patients having undergone allogeneic or autologous stem cell transplantation.
Interventions
- DRUG placebo
- DRUG activated recombinant human factor VII
- PROCEDURE standard therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2001-04 |
| Est. Completion | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01562158
The ClinicalTrials.gov registry entry for NCT01562158 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01562158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01562158 about?
NCT01562158 is a clinical study titled "Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation". This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the efficacy of placebo and activated recombinant human factor VII in patients having undergone allogeneic or autologous stem cell transplantation.
What is the current status of trial NCT01562158?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2001-04. Estimated completion is 2003-10.
What interventions are being tested in trial NCT01562158?
The interventions under investigation include: placebo (DRUG), activated recombinant human factor VII (DRUG), standard therapy (PROCEDURE).
Who is sponsoring clinical trial NCT01562158?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.